IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation

Dvir, Roee; Paloschi, V.; Canducci, Filippo; Dell’Antonio, Giacomo; Racca, Sara; Caldara, Rossana; Pantaleo, Giuseppe; Clementi, Massimo; Secchi, Antonio

doi:10.1038/s41598-017-06915-4

Cited by 4 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dvir et al hypothesized the association of the interferon-λ family with BKVN due to the antiviral protection of the epithelium. They found a single-nucleotide polymorphism rs12979860 in the genomic region of interleukin-28B has predictive value for identifying high-risk patient progression from viremia to BKVN [ 139 ]. Ho et al described the correlation of urine C-X-C motif chemokine ligand 10 (CXCL10) with BK viremia.…”

Section: Balancing the Rejection And Infectionmentioning

confidence: 99%

BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection

Shen

Lien

et al. 2021

Viruses

View full text Add to dashboard Cite

BK polyomavirus nephropathy (BKVN) and allograft rejection are two closely-associated diseases on opposite ends of the immune scale in kidney transplant recipients. The principle of balancing the immune system remains the mainstay of therapeutic strategy. While patient outcomes can be improved through screening, risk factors identification, and rapid reduction of immunosuppressants, a lack of standard curative therapy is the primary concern during clinical practice. Additionally, difficulty in pathological differential diagnosis and clinicopathology’s dissociation pose problems for a definite diagnosis. This article discusses the delicate evaluation needed to optimize immunosuppression and reviews recent advances in molecular diagnosis and immunological therapy for BKVN patients. New biomarkers for BKVN diagnosis are under development. For example, measurement of virus-specific T cell level may play a role in steering immunosuppressants. The development of cellular therapy may provide prevention, even a cure, for BKVN, a complex post-transplant complication.

show abstract

Section: Balancing the Rejection And Infectionmentioning

confidence: 99%

BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection

Shen

Lien

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…A single nucleotide polymorphism (SNP) of IL28B (C/T polymorphism rs12979860) was associated with presence of PVAN, discriminating these patients from those with viremia without any renal involvement [ 185 ].…”

Section: Chronic Allograft Dysfunction (Cad)mentioning

confidence: 99%

“…Urinary exosomal bkv-miR-B1-5p and bkv-miR-B1-5p/miR-16 Excellent diagnostic accuracy for PVAN Kim M et al [183] Urinary CXCL10 Associated with subclinical tubule-interstitial inflammation and viremia Ho J et al [184] IL28B SNP C/T (rs12979860) Associated with presence of PVAN in viremic patients Dvir R et al [185] Urinary exosomal bkv-miR-B1-5p and bkv-miR-B1-5p/miR-16, two miRNAs encoded by PVAN, have both demonstrated very high discriminative capacity for this complication (ROC AUC 0.98 for each) as compared with that of commonly used surrogate biomarkers, such as plasma viral load [183].…”

Section: Biomarker Main Features Authormentioning

confidence: 99%

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Quaglia

Merlotti

Guglielmetti

et al. 2020

IJMS

View full text Add to dashboard Cite

New biomarkers of early and late graft dysfunction are needed in renal transplant to improve management of complications and prolong graft survival. A wide range of potential diagnostic and prognostic biomarkers, measured in different biological fluids (serum, plasma, urine) and in renal tissues, have been proposed for post-transplant delayed graft function (DGF), acute rejection (AR), and chronic allograft dysfunction (CAD). This review investigates old and new potential biomarkers for each of these clinical domains, seeking to underline their limits and strengths. OMICs technology has allowed identifying many candidate biomarkers, providing diagnostic and prognostic information at very early stages of pathological processes, such as AR. Donor-derived cell-free DNA (ddcfDNA) and extracellular vesicles (EVs) are further promising tools. Although most of these biomarkers still need to be validated in multiple independent cohorts and standardized, they are paving the way for substantial advances, such as the possibility of accurately predicting risk of DGF before graft is implanted, of making a “molecular” diagnosis of subclinical rejection even before histological lesions develop, or of dissecting etiology of CAD. Identification of “immunoquiescent” or even tolerant patients to guide minimization of immunosuppressive therapy is another area of active research. The parallel progress in imaging techniques, bioinformatics, and artificial intelligence (AI) is helping to fully exploit the wealth of information provided by biomarkers, leading to improved disease nosology of old entities such as transplant glomerulopathy. Prospective studies are needed to assess whether introduction of these new sets of biomarkers into clinical practice could actually reduce the need for renal biopsy, integrate traditional tools, and ultimately improve graft survival compared to current management.

show abstract

“…The viral reactivation is asymptomatic, and the infection is often only revealed by kidney failure. Despite a significant increase in clinical awareness and a better understanding of BKPyV infections, BKPyVAN still poses a real problem for kidney transplant patients [16]. The only available treatment strategy for BKPyVAN seeks to reduce virus replication while avoiding graft rejection; this corresponds to a timely level reduction of immunosuppression and (in some cases) antiviral therapy initiation [14].…”

Section: Bkpyv-associated Nephropathymentioning

confidence: 99%

Pre-Transplantation Assessment of BK Virus Serostatus: Significance, Current Methods, and Obstacles

Dakroub

Touzé

Akl

et al. 2019

Viruses

View full text Add to dashboard Cite

The immunosuppression required for graft tolerance in kidney transplant patients can trigger latent BK polyomavirus (BKPyV) reactivation, and the infection can progress to nephropathy and graft rejection. It has been suggested that pre-transplantation BKPyV serostatus in donors and recipients is a predictive marker for post-transplantation BKPyV replication. The fact that research laboratories have used many different assay techniques to determine BKPyV serostatus complicates these data analysis. Even studies based on the same technique differed in their standard controls choice, the antigenic structure type used for detection, and the cut-off for seropositivity. Here, we review the different BKPyV VP1 antigens types used for detection and consider the various BKPyV serostatus assay techniques’ advantages and disadvantages. Lastly, we highlight the obstacles in the implementation of a consensual BKPyV serologic assay in clinics (e.g., the guidelines absence in this field).

show abstract

IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation

Cited by 4 publications

References 39 publications

BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection

BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection

Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction

Pre-Transplantation Assessment of BK Virus Serostatus: Significance, Current Methods, and Obstacles

Contact Info

Product

Resources

About